The Philippines would not halt infrastructure projects involving Chinese firms blacklisted by ally the US and would make its own decisions, not those of a foreign power, Philippine President Rodrigo Duterte’s spokesman said yesterday.
Duterte would not follow Washington’s move to sanction Chinese firms involved in building and militarizing artificial South China Sea islands, because infrastructure was a national priority, his spokesman Harry Roque said.
‘NOT A VASSAL’
“We are not a vassal state of any foreign power and we will pursue our national interest,” Roque told a regular news conference. “Our national interest is to ensure flagship projects are completed.”
Duterte has a race against time to make headway in his US$180 billion infrastructure overhaul, which is fraught with complications.
The US, a defense treaty ally of the Philippines, has blacklisted 24 Chinese companies and targeted individuals over the building of military facilities on submerged reefs in disputed waters, escalating tensions with Beijing.
The Philippine minister of foreign affairs had recommended that his government terminate deals with those entities.
Duterte’s non-intervention could cause some friction, as several of China’s islands challenge his country’s interests, most notably Mischief Reef (Meiji Reef, 美濟礁), built within its 200 nautical mile (370km) exclusive economic zone and equipped with missiles capable of striking the Philippines.
Among firms involved are China Communications Construction Co, which has teamed up with a Philippine partner for a US$10 billion airport project, and its subsidiary, China Harbour Engineering Co, which is partnering on a US$1.2 billion reclamation project with the firm of tycoon Dennis Uy, Duterte’s associate and biggest election campaign donor.
China Harbour is also to partner with the Philippines’ richest family on a separate US$1.86 billion reclamation venture.
Opposition lawmaker Risa Hontiveros yesterday filed a Senate resolution to investigate possible collusion by Filipinos over China’s artificial islands.
“It is not hard to suspect dubious engagement by either party,” Hontiveros said.
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very